Pluri (FRA:4DX) Total Operating Expense: €22.76 Mil (TTM As of Mar. 2026)


FRA:4DX Pluri Inc FRA:4DX
25 GF Score
Price €5.60
GF Value €17.25
! 6 Warning Signs
View Full Analysis

What is Pluri Total Operating Expense?

Pluri FRA:4DX 25 Total Operating Expense is €22.76 Mil as of Mar. 2026. GuruFocus rates FRA:4DX with a GF Score™ of 25/100 and a GF Value™ of €17.25. The stock has 6 warning signs investors should review.

Pluri's Total Operating Expense for the three months ended in Mar. 2026 was €5.70 Mil. Pluri's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €22.76 Mil.

Pluri Total Operating Expense Related Terms

Pluri Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Pluri's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pluri Total Operating Expense Chart

Pluri Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.02 39.57 25.41 20.88 19.79

Pluri Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.12 5.92 5.51 5.63 5.70
FRA:4DX
25GF Score
Pluri Inc FRA:4DX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pluri Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €22.76 Mil mean?
Pluri (FRA:4DX) has a Total Operating Expense of €22.76 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pluri and its competitors.
Is Pluri's Total Operating Expense too high?
Pluri's current Total Operating Expense is €22.76 Mil. Overall, Pluri has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Total Operating Expense compare to MRKR and VYNE?
Pluri's Total Operating Expense of €22.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Pluri and its competitors. Pluri's current Total Operating Expense is €22.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Total Operating Expense of €22.76 Mil. The stock's GF Value™ is €17.25, compared to a current price of €5.60 — trading 67.5% below its estimated fair value. The current Total Operating Expense is €22.76 Mil. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Total Operating Expense is €22.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pluri (FRA:4DX) Overvalued in 2026?

Based on GuruFocus' analysis, Pluri stock appears to be undervalued. The current stock price of €5.60 is trading 67.5% below its estimated GF Value™ of €17.25.

Key valuation signals for FRA:4DX:

  • Total Operating Expense: €22.76 Mil
  • GF Value™: €17.25 vs. price of €5.60 (67.5% below fair value)
  • GF Score™: 25/100 with 6 warning signs

No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pluri Business Description

Other Exchanges PLUR:USAPLUR:Israel
Address MATAM Advanced Technology Park, Building No. 5, Haifa, ISR, 3508409
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score

Get the complete analysis for FRA:4DX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price
€17.25
GF Value